<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="34806"><DrugName>NK1 antagonists, Lilly</DrugName><DrugSynonyms><Name><Value>LY-382968</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NK1 antagonists, Lilly</Value></Name><Name><Value>lanepitant analogs, Lilly</Value></Name><Name><Value>substance P antagonists, Eli Lilly</Value></Name><Name><Value>360561-19-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="28" type="ciIndication"><TargetEntity id="10003246" type="MEDDRA"></TargetEntity><TargetEntity id="D001168" type="MeSH"></TargetEntity><TargetEntity id="-1504014133" type="omicsDisease"></TargetEntity><TargetEntity id="720" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="266" type="Action"><TargetEntity id="316" type="Mechanism">Tachykinin NK1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01432" type="ciTarget"><TargetEntity id="200558287368693" type="siTarget">Substance-P receptor</TargetEntity><TargetEntity id="1139" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="20">Pain</Indication><Indication id="210">Migraine</Indication><Indication id="28">Arthritis</Indication><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="266">NK1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2C</Code><Name>ANTI-MIGRAINE PREPARATIONS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-07T14:17:50.000Z</LastModificationDate><ChangeDateLast>2009-04-28T16:37:21.000Z</ChangeDateLast><AddedDate>2001-06-25T15:21:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; was investigating a number of NK1 (substance P) antagonists for the potential treatment of persistent pain, migraine, arthritis and asthma [&lt;ulink linkID="413450" linkType="reference"&gt;413450&lt;/ulink&gt;], [&lt;ulink linkID="306964" linkType="reference"&gt;306964&lt;/ulink&gt;]. However, by March 2005, Eli Lilly had discontinued all research into anti-inflammatory compounds [&lt;ulink linkID="593986" linkType="Reference"&gt;593986&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2005, preclinical data on a novel series of NK1 antagonists were presented at the 229th ACS meeting in San Diego, CA. The most potent compound (structure shown) had a Ki at NK1 of 0.51 nM, solubility of 121 microM (SGI) and a GFT ED50 of 0.3 mg/kg (0.5 h). In addition, this compound was potent and had good duration in the gerbil foot tap assay [&lt;ulink linkID="589387" linkType="Reference"&gt;589387&lt;/ulink&gt;]. Another  series  containing oxazole ring instead of pyrrolidine was also presented. The lead compound from this series had a Ki value of 0.2 nM, an ED50 in the gerbil foot tap assay of 0.3, SimGI solubility of 101 microM and low human metabolism [&lt;ulink linkID="589389" linkType="Reference"&gt;589389&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;Lilly has had a number of substance P programs including &lt;ulink linkID="10958" linkType="Drug"&gt;lanepitant&lt;/ulink&gt; (qv) which had entered clinical trials by 2000. &lt;ulink linkID="10958" linkType="Drug"&gt;Lanepitant&lt;/ulink&gt; has poor oral bioavailability and causes irritation when administered iv. Lilly therefore returned to earlier SAR work in an effort to develop a second-generation clinical candidate to overcome these shortcomings. Replacement of the 2-[4-(piperidin-1-yl)piperidin-1-yl]acetyl side chain of &lt;ulink linkID="10958" linkType="Drug"&gt;lanepitant&lt;/ulink&gt; with non-basic groups has led to a series of NK1 antagonists with improved PK profiles. One of the more promising compounds  was nonirritating and displayed an IC50 value of 0.98 nM, an F value of 47% (dog) and 67% microsome stability in dog liver [&lt;ulink linkID="413450" linkType="reference"&gt;413450&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="28">Arthritis</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="593986" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="210">Migraine</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="593986" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="593986" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="593986" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>2001-06-25T00:00:00.000Z</StatusDate><Source id="413450" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2001-06-25T00:00:00.000Z</StatusDate><Source id="413450" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2001-06-25T00:00:00.000Z</StatusDate><Source id="413450" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>1998-11-25T00:00:00.000Z</StatusDate><Source id="306964" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01432"><Name>NK1 receptor</Name><SwissprotNumbers><Swissprot>P14600</Swissprot><Swissprot>P25103</Swissprot><Swissprot>P30547</Swissprot><Swissprot>P30548</Swissprot><Swissprot>Q5DUB1</Swissprot><Swissprot>Q5DUB3</Swissprot><Swissprot>Q98982</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(=O)N(Cc1ccccc1OC)C[C@@H](Cc2c[nH]c3c2cccc3)NC(=O)COc4ccc(cc4)c5csnn5</Smiles><Smiles>c1ccc(c(c1)[C@@H]2CCCN2C(=O)c3c(n(nn3)Cc4cc(cc(c4)C(F)(F)F)C(F)(F)F)N5CCOCC5)Cl</Smiles><Smiles>c1ccc(c(c1)c2c(oc(n2)C3CC3)C(=O)c4c(n(nn4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F)n6ccnc6)Cl</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>